Sign In
Buy PRVB
$24.98
+0 (+0%)
At Close: Jul 24, 2023
Provention Bio: Oversold Territory, An Attractive Buying Opportunity
06:55pm, Friday, 09'th Apr 2021
Provention Bio is oversold, and the stock is trading at an attractive price level. I expect a sharp rebound shortly. The key question is "when" will Teplizumab be approved, not whether Teplizumab will
What's Going On With CELC Stock And PRVB Stock Today?
09:22am, Friday, 09'th Apr 2021
Celcuity Inc (NASDAQ: CELC) shares are trading higher after the company announced a worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize gedatolisib. Celcuity is a c
Provention Bio Stock Craters After FDA Flags Deficiencies In PK Profiles From Teplizumab Trials For Diabetes
06:30am, Friday, 09'th Apr 2021
Provention Bio Inc (NASDAQ: PRVB) revealed it had received a notification on April 2 from the FDA stating that the agency has identified deficiencies that preclude discussion of labeling and post-
RED BANK, N.J., April 8, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that t
Moving Average Crossover Alert: Provention Bio (PRVB)
08:20am, Friday, 26'th Mar 2021
Provention Bio (PRVB) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q4 2020 Results - Earnings Call Transcript
05:05pm, Thursday, 25'th Feb 2021
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q4 2020 Results - Earnings Call Transcript
Week In Review: Yuanxin Raises $465 Million For Online Healthcare Company Miaoshou Doctor
01:56pm, Sunday, 21'st Feb 2021
Week In Review: Yuanxin Raises $465 Million For Online Healthcare Company Miaoshou Doctor
Provention Bio Announces China Deal For Autoimmune Program
02:18pm, Thursday, 18'th Feb 2021
Provention Bio Inc (NASDAQ: PRVB) is making its way into China with a new deal with a subsidiary of Huadong Medicine to work on PRV-3279, a bispecific antibody-based molecule targeting CD32B and C
Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock
07:03pm, Wednesday, 13'th Jan 2021
RED BANK, N.J., Jan. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pr
Is the Options Market Predicting a Spike in Provention Bio (PRVB) Stock?
10:32am, Tuesday, 12'th Jan 2021
Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.
Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market
02:09pm, Thursday, 07'th Jan 2021
Provention Bio is focused on slowing down, or actually preventing in some cases, the onset of autoimmune conditions. Provention's first therapeutic, teplizumab, looks set for approval in mid-2021 in w
Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference
04:05pm, Wednesday, 06'th Jan 2021
RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that man
Provention Bio to Present at the Stifel Virtual Healthcare Conference
07:30am, Wednesday, 11'th Nov 2020
RED BANK, N.J., Nov. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that managem
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2020 Results - Earnings Call Transcript
08:27pm, Saturday, 07'th Nov 2020
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2020 Results - Earnings Call Transcript
Provention: An Undercovered Healthcare Stock You Should Know About
09:41am, Tuesday, 03'rd Nov 2020
Provention is leading a set of new drugs that protect beta cell functions, enabling endogenous insulin production in type 1 diabetes patients. The stock may have a PDUFA late next year; rolling BLA su
